Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
Andrew X. Zhu(Massachusetts General Hospital), Li‐Tzong Chen(National Health Research Institutes), Étienne Dorval(Centre Hospitalier Universitaire de Tours), Masatoshi Kudo(Kindai University), Eric Assénat, Kevin Perraud(Novartis (Switzerland)), Junji Furuse(Kyorin University), Bruno Daniele(Azienda Ospedaliera G.Rummo), Dalila Sellami(Novartis (United States)), Annette Jappe(Novartis (Switzerland)), Markus Peck‐Radosavljevic(Medical University of Vienna), Arndt Vogel(Medizinische Hochschule Hannover), Oezlem Anak(Novartis (Switzerland)), Armando Santoro(IRCCS Humanitas Research Hospital), Jean-Frédéric Blanc(Hôpital Saint-André), Stéphane Cattan(Université Lille Nord de France), Ronnie T.P. Poon(Hong Kong University of Science and Technology), Yoon‐Koo Kang(Ulsan College), Chao‐Long Chen(Memorial Hospital of South Bend), Ho Yeong Lim(Samsung Medical Center)
Cited by 569
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k